

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

205637Orig1s000

MICROBIOLOGY / VIROLOGY REVIEW(S)

Product Quality Microbiology Review

14 April 2014

NDA: 205637

Drug Product Name

Proprietary:

Bunavail

Non-proprietary:

Buprenorphine hydrochloride
and naloxone hydrochloride
dihydrate

Review Number: 1

Dates of Submission(s) Covered by this Review

<u>Submit</u>	<u>Received</u>	<u>Review Request</u>	<u>Assigned to Reviewer</u>
06 AUG 2013	07 AUG 2013	31 OCT 2013	31 OCT 2013

Applicant/Sponsor

Name:

BioDelivery Sciences International

Address:

801 Corporate Center Dr.

Suite 210

Raleigh, NC 27607

Representative:

Renee Boerner, Ph.D.

Telephone:

919-582-9050


Name of Reviewer:

John W. Metcalfe, Ph.D.

Conclusion:

Recommended for Approval

Product Quality Microbiology Data Sheet

- A.
1. **TYPE OF SUBMISSION:** A 505 (b)(2) New Drug Application
 2. **SUBMISSION PROVIDES FOR:** Marketing authorization
 3. **MANUFACTURING SITE:**
 (b) (4)
 4. **DOSAGE FORM, ROUTE OF ADMINISTRATION AND STRENGTH/POTENCY:**
 - Buccal film
 - Buccal administration
 - , 2.1/0.35, 4.2/0.7, 4.3/1.04 mg buprenorphine/naloxone
 5. **METHOD(S) OF STERILIZATION:** The drug product is non-sterile
 6. **PHARMACOLOGICAL CATEGORY:** The drug product is indicated for the maintenance of treatment of opioid dependence
- B. **SUPPORTING/RELATED DOCUMENTS:** None
- C. **REMARKS:**
The NDA is submitted electronically in the CTD format.

File Name: N205637R1.doc

Executive Summary

I. Recommendations

- A. Recommendation on Approvability** – NDA 205637 is recommended for approval from the standpoint of product quality microbiology.
- B. Recommendations on Phase 4 Commitments and/or Agreements, if Approvable** – Not applicable.

II. Summary of Microbiology Assessments

- A. Brief Description of the Manufacturing Processes that relate to Product Quality Microbiology** – (b) (4)
- B. Brief Description of Microbiology Deficiencies** – There are no product quality microbiology deficiencies identified.
- C. Assessment of Risk Due to Microbiology Deficiencies** – Not applicable.
- D. Contains Potential Precedent Decision(s)** No

III. Administrative

- A. Reviewer's Signature** _____
John W. Metcalfe, Ph.D.
Senior Microbiology Reviewer
CDER/OPS/NDMS
- B. Endorsement Block** _____
Stephen E. Langille, Ph.D.
Senior Microbiology Reviewer
CDER/OPS/NDMS
- C. CC Block**
N/A

7 Page(s) has been Withheld in Full as b4 (CCI/TS) immediately following this page

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

JOHN W METCALFE
04/14/2014

STEPHEN E LANGILLE
04/14/2014

PRODUCT QUALITY MICROBIOLOGY FILING CHECKLIST

NDA Number: 205637

Applicant: Biodelivery
Sciences International, Inc.

Letter Date: 06 August 2013

Drug Name: Bunavail

NDA Type: 505(b)(2)

Stamp Date: 07 August 2013

The following are necessary to initiate a review of the NDA application:

	Content Parameter	Yes	No	Comments
1	Is the product quality microbiology information described in the NDA and organized in a manner to allow substantive review to begin? Is it legible, indexed, and/or paginated adequately?	X		Module 3.2.P.
2	Has the applicant submitted an overall description of the manufacturing processes and microbiological controls used in the manufacture of the drug product?	X		Module 3.2.P.3.
3	Has the applicant submitted protocols and results of validation studies concerning microbiological control processes used in the manufacture of the drug product?		X	Not applicable to application.
4	Are any study reports or published articles in a foreign language? If yes, has the translated version been included in the submission for review?		X	
5	Has the applicant submitted preservative effectiveness studies (if applicable) and container-closure integrity studies?		X	Not applicable to application.
6	Has the applicant submitted microbiological specifications for the drug product and a description of the test methods?		X	The applicant proposes to omit microbial limits testing.
7	Has the applicant submitted the results of analytical method verification studies?		X	Not applicable to application.
8	Has the applicant submitted all special/critical studies/data requested during pre-submission meetings and/or discussions?		X	Not applicable to application.
9	If sterile, are extended post-constitution and/or post-dilution hold times in the draft labeling supported by microbiological data?		X	Not applicable to application.
10	Is this NDA fileable? If not, then describe why.	X		

Additional Comments: The non-sterile drug product is a topical patch for buccal administration. The applicant's rationale for omitting microbial limits testing at release will be evaluated during the review cycle.

John W. Metcalfe, Ph.D.
Senior Microbiology Reviewer, CDER/OPS/NDMS

18 September 2013

Date

Stephen E. Langille, Ph.D.
Senior Microbiology Reviewer, CDER/OPS/NDMS

18 September 2013

Date

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

JOHN W METCALFE
09/18/2013

STEPHEN E LANGILLE
09/18/2013